Takeda Pharmaceutical Co Ltd ADR
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $1,213,211,320 | $1,112,796,000 | $1,106,685,000 | $1,053,400,000 |
Gross Profit | 660,345,606 | 732,735,000 | 722,010,000 | 671,300,000 |
EBITDA | 456,219,938 | 316,467,000 | 439,424,000 | 181,269,000 |
EBIT | 262,139,397 | 111,312,000 | 257,788,000 | -8,500,000 |
Net Income | 105,509,960 | -11,802,000 | 124,243,000 | -103,200,000 |
Net Change In Cash | 1,213,211,320 | 1,112,796,000 | 1,106,685,000 | 1,053,400,000 |
Free Cash Flow | 317,469,406 | 325,403,000 | 140,355,000 | 173,366,000 |
Cash | 655,384,084 | 681,486,000 | 350,008,000 | 385,113,000 |
Basic Shares | 3,204,936 | 3,154,932 | 3,176,352 | 3,163,218 |
Annual Financials
| Values in thousands | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
Revenue | $4,581,551,000 | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 |
Gross Profit | 3,001,334,000 | 2,832,257,000 | 2,783,406,000 | 2,462,160,000 |
EBITDA | 1,210,512,000 | 1,143,936,000 | 1,284,067,000 | 1,183,213,000 |
EBIT | 449,116,000 | 499,475,000 | 619,667,000 | 600,062,000 |
Net Income | 107,928,000 | 144,067,000 | 317,017,000 | 230,059,000 |
Net Change In Cash | 4,581,551,000 | 4,263,762,000 | 4,027,478,000 | 3,569,006,000 |
Free Cash Flow | 856,387,000 | 235,614,000 | 343,467,000 | 937,068,000 |
Cash | 385,113,000 | 457,800,000 | 533,530,000 | 849,695,000 |
Basic Shares | 3,210,710 | 3,160,686 | 3,139,744 | 3,154,338 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0.20 |
2025-09-30 | -$0.02 |
2025-06-30 | $151 |
2025-03-31 | -$0.22 |
